2nd Quarterly Report for Diamyd Medical AB (publ), Fiscal Year 2006/2007
(SWEDEN OMX: DIAM B; USA OTCQX: DMYDY)
December 1, 2006 - February 28, 2007
• In December a patent license was executed with Centre National de la Recherche
Scientifique (CNRS) in Paris, giving the Company exclusive rights to CNRS's GAD
gene therapeutic technology.
• At the Annual Shareholders' Meeting held on December 11, 2006:
- Joseph Janes was elected Chairman of the Board and Hans Wigzell, Professor,
joined the Board.
- The Board was authorized to issue up to 600,000 new shares for cash or other
consideration until the next Annual Shareholders' Meeting.
- A plan to issue up to 250,000 options to employees and close collaborators of
the Diamyd Group was approved.
• In December SEK 10.2 million (US$ 1.49 million) was raised at market price
from a Swedish institutional investor.
• At the end of December the US$ 3 million convertible investment in Protein
Sciences Corporation was converted into a fully diluted equity position of
approximately 6.7 percent of the capital and votes.
• A “Pre-IND/End of Phase II” meeting was held at the end of January with the
U.S. Food and Drug Administration (FDA) to discuss a Phase III clinical program
using Diamyd® to treat type 1 diabetes.
• Details of the plans for U.S. and European Phase III clinical programs for
type 1 diabetes were announced after the reporting period.
• In June 2007, results from a 160-patient Phase II/III 18 month study in
autoimmune type 2 diabetes (LADA) are planned to be publicly announced.
• Net sales were SEK 115,000 (US$ 16,400) compared to SEK 377,000 (US$ 53,900)
for the same period of the prior fiscal year.
• Loss before Taxes was SEK 13.8 million (US$ 2.0 million) compared to SEK 6.0
million (US$ 0.9 million) for the same period of the prior fiscal year.
• Liquid assets were SEK 95.9 million (US$ 13.4 million) as of February 28,
2007. This is compared with SEK 79.7 million (US$ 11 million) as of February 28,
2006.
• Loss per share was SEK 1.4 (US$ 0.2) compared to SEK 0.7 (US$ 0.1) for the
same period of the prior fiscal year.
CEO OVERVIEW AND COMPANY HIGHLIGHTS
During the past quarter, Diamyd Medical continued to advance its development of
Diamyd® into a first-in-class therapy for type 1 and autoimmune type 2 (LADA)
diabetes. A dialogue was initiated in January with the FDA at a “pre-IND/end of
Phase II” meeting. The outcome of the meeting was positive and constructive and
we anticipate starting Phase III registration trials in the US and Europe later
this year.
These trials would each comprise approximately 300 type 1 diabetes patients.
Enrollment time is estimated to be approximately 9 months. The main study period
would be 15 months. The primary endpoint will be the measured levels of
meal-stimulated C-peptide as a direct marker of endogenous insulin production.
Trends in blood glucose levels and insulin dose will be evaluated.
The main study period of our Phase II/III clinical trial in 160 autoimmune type
2 diabetes (LADA) patients is close to completion. The 18 months results from
this study are planned to be publicly announced in June 2007.
To complement our GAD patent portfolio, an exclusive license agreement was
concluded in December 2006 with Centre National de la Recherche Scientifique in
Paris for rights to the patent portfolio covering therapeutic use of GAD via
viral vectors. We believe this technology can become important in applications
where GAD delivery to nervous tissue is required.
Partnership discussions with pharmaceutical companies regarding
commercialization of Diamyd® are ongoing. Concurrently, the Company continues
its preparations to take Diamyd® into Phase III studies necessary for market
approval. Several options are thereby kept open.
Anders Essen-Möller, CEO and President of Diamyd Medical.
BUSINESS OVERVIEW
The Company's vision is that there is a cure to be found for autoimmune diabetes
and the Company's mission is to contribute in the global effort to find this
cure and to eliminate complications from the disease. Accordingly, the Company
currently develops therapeutics from two independent platform technologies. One
of these platforms relies on the GAD65 molecule and the other on a viral
delivery system for proteins, in particular, to nervous tissue. Therapeutics for
diseases other than diabetes are also being developed.
Business Model
Diamyd Medical's business model includes identifying candidate therapies and
developing them through clinical trials before commercialization through
partnerships. Development and marketing of related diagnostic products may be
undertaken to prepare the market for subsequent drug launches.
Diamyd Medical's business model leverages a focused in-house team with highly
qualified skills and expert outsourcing partners, e.g. CROs and CMOs, to
facilitate drug development. This model efficiently manages costs through
resource flexibility while ensuring delivery of quality results as the Company's
projects move forward.
Diabetes
The International Diabetes Federation has estimated that the number of diagnosed
and undiagnosed individuals with diabetes is about 230 million persons
world-wide. The number of individuals with diabetes increased by 6 million in
2006. Diabetes increased by 11% in the US. About 3-10% of the individuals
diagnosed with diabetes have type 1 diabetes with incidence rates varying by
country and ethnicity. About the same amount of patients have autoimmune type 2
diabetes, the LADA form of the disease. The costs associated with diabetes in
the western world are about 7% of total health care budgets, or more than US$
100 billion in the United States alone.
DIAMYD® CLINICAL TRIALS: TYPE 1 DIABETES
In August, 2006, the Company announced positive results from a 15 months Phase
II trial in 70 children and adolescents with type 1 diabetes. Significant
efficacy was demonstrated in preserving beta cell function. On average, the 35
patients that received Diamyd® experienced only half the decline in
meal-stimulated insulin secretion, as measured by C-peptide levels, compared to
placebo. In patients treated within 3 months of diagnosis, the Diamyd®-treated
patients actually showed an improvement in endogenous insulin secretion. In
addition, the results strongly support the safety of the drug. The treatment
consists of only two injections of Diamyd® and was well received by patients,
their doctors and family members.
The trial is now in a 15 month follow-up phase with results due in about 10
months.
DIAMYD® CLINICAL TRIALS: AUTOIMMUNE TYPE 2 DIABETES (LADA)
An ongoing phase II/III study in 160 patients with autoimmune type 2 diabetes
(LADA) is being conducted at 17 clinical sites in Sweden. Results from this 18
month trial are planned for June 2007.
In the previously reported dose-finding trial in LADA patients the 20µg dose of
Diamyd® was found to be the most effective and was selected for further
development. This dose was found to significantly improve both C-peptide levels
and A1C at two years after treatment. Five year follow up results are due
mid-2008.
Chronic Pain
In the US, nearly one third of the population experiences severe chronic pain at
some point in life, and, according to the American Pain Society, only one in
four patients with chronic pain receive adequate treatment. Approximately 1.7
million people in the US and as many as 38 million worldwide suffer from
moderate to severe neuropathic pain associated with diabetes, back pain,
HIV/AIDS neuropathy, spinal cord injury, postherpetic neuralgia or other
diseases. The neuropathic pain market in the United States is expected to be
worth more than US$ 2 billion by 2009.
NTDDS
Diamyd Inc. in Pittsburgh is developing a replication deficient viral delivery
system for proteins, in particular, to nervous tissues. This Nerve Targeted
Drug Delivery System (NTDDS) has several advantages over other gene delivery
strategies as the DNA that encodes the delivered gene does not integrate into
the chromosome and, therefore reduces the risk of side effects. NTDDS has the
capacity to deliver multiple genes and is well suited for development of a
multitude of projects. Diamyd Inc. is discussing joint development of various
projects with third party biotechnology companies. The NTDDS lead projects are
therapeutics for pain using Enkephalin and GAD. These projects are both in a
preclinical stage.
GAD and other neurological diseases
Apart from being a major autoantigen in autoimmune diabetes, GAD65 is also an
enzyme that converts the excitatory neurotransmitter glutamate into the
inhibitory neurotransmitter GABA. Several neurological and movement related
disorders may be due to disturbances in the Glutamate-GABA balance, and GAD65
may come to play an important role as a component in future medications for
treatment of such diseases.
Diamyd Medical has sublicensed rights to the GAD65 gene to Neurologix, Inc. for
the development of a GAD-based therapy to treat Parkinson's disease. A Phase I
trial with patients having Parkinson's disease has been completed. Primary
objectives of the study regarding safety and tolerability were successfully met.
Additionally, indications of efficacy were shown.
FINANCIAL PERFORMANCE
At the Annual Shareholders' Meeting of Diamyd Medical AB (publ) that was held in
Stockholm, Sweden, on December 11, 2006, Joseph Janes, U.S.A, was elected
Chairman of the Board. Peter Rothschild, Björn O. Nilsson and Anders
Essen-Möller were all re-elected and Hans Wigzell was newly elected.
Additionally, the Board of Directors was authorized to decide, at one or more
occasions until the next Annual Shareholders' Meeting, to issue new shares with
consideration by set-off, in cash or with other conditions and without regard to
pre-emption rights. The total number of shares that can be issued based on this
authorization should not exceed 600,000. At full execution of all of the above
the dilution is calculated to approximately 6 percent.
The Meeting also approved the Board of Directors' proposal to implement an
option scheme including the issuance of 250,000 purchase options to employees
and close collaborators of the Diamyd Group. Each purchase option shall entitle
the holder to acquire one series B-share. At full execution of all of the above
the dilution is calculated to approximately 2.5 percent.
In December 2006, we accepted a private investment from a Swedish institutional
investor with support of the authorization (see above) given by the Annual
Shareholders' Meeting. Issuance of 70,000 new shares at market price resulted in
nearly 10.2 MSEK (US$ 1.5 million) of additional capital for the company. In
December 2006, our 2005 investment in Protein Sciences Corporation was converted
into an equity stake equal to approximately 6.7 percent of the fully diluted
equity. In addition to being a manufacturing partner for Diamyd, Protein
Sciences is also developing a late stage non-egg-based flu vaccine product,
FluBlØk™. This drug candidate is based upon next-generation recombinant
manufacturing technologies.
Sales - Sales during the three month period amounted to 115 kSEK compared to 377
kSEK during the same period last year. Sales fluctuate from quarter to quarter
and consist of Diamyd-related products such as GAD-protein sold to academic
researchers.
Costs - Costs for the Group amounted to 15.4 MSEK (6.9 MSEK) during the three
month period. The increased costs are incurred by development of the
manufacturing process and research and development cost in the subsidiary Diamyd
Inc.
Loss -The net loss for the Group for the three-month period amounted to 13.8
MSEK (6.0 MSEK).
Financial Position and Liquidity - The Group's liquid assets amounted to 95.9
MSEK as of February 28th, 2007 (79.7 MSEK).
Investments - No significant investments were made during the period.
Change in Equity - As of February 28th, 2007, the Company's equity amounted to
132.2 MSEK (120.0 MSEK), resulting in a solvency ratio of 93.9 % (92.8 %).
Personnel - The Company had 11 (7) employees as of February 28th, 2007.
Parent Company - The Parent Company's net turnover amounted to 0 SEK as all
sales are conducted in subsidiary companies. The period's investments were 0
SEK.
FINANCIAL RESULTS
Group's Consolidated Income Statement
kSEK
6 months 6 months 3 months 3 months 12 months
Sep-Feb Sep-Feb Dec-Feb Dec-Feb Sep-Aug
2006-2007 2005-2006 2006-2007 2005-2006 2005-2006
OPERATING EXPENSES
Net sales Note 1 175 595 115 377 4,323
Other Operating Income 381 - 360 - 126
Total Operating Income 557 595 476 377 4,449
Operating Expenses Note 2
Cost Of Goods Sold -7 -383 -3 -6 -166
Research and Development -12,968 -7,752 -8,415 -3,359 -23,167
Patents -722 -314 -214 -35 -1,471
Personnel -5,848 -4,594 -3,113 -2,335 -9,876
Other External Expenses -5,075 -2,176 -3,089 -938 -8,680
Depreciation, Patents -1,094 -324 -517 -162 -1,626
Depreciation, Equipment -66 -57 -33 -29 -115
Total Operating Expenses -25,781 -15,600 -15,385 -6,864 -45,101
Operating Loss -25,225 -15,005 -14,910 -6,487 -40,652
FINANCIAL INCOME AND EXPENSES
Dividends from Holdings - - - - 250
Interest Income 1,263 1,112 562 436 1,808
Interest Expense -528 - 548 - -56
Total Financial Income and Expense 734 1,112 1,109 436 2,002
Loss before Taxes -24,490 -13,893 -13,800 -6,051 -38,650
Taxes - - - - -
NET LOSS FOR THE PERIOD -24,490 -13,893 -13,800 -6,051 -38,650
Group's Consolidated Balance Sheet
kSEK
Feb 28 Feb 28 Aug 31
2007 2006 2006
ASSETS
Non-Current Assets
Intangible assets 15,688 18,430 16,745
Tangible assets 251 170 133
Financial assets Note 3 21,418 800 800
Total Non-Current Assets 37,356 19,400 17,678
Current Assets
Inventory 14 121 12
Trade and Other Receivables
Trade Receivables 322 512 148
Other Receivables 3,707 1,761 2,879
Prepaid tax 404 198 326
Prepaid Expenses and Accrued Income 3,072 3,960 2,600
Total Trade and Other Receivables 7,505 6,431 5,953
Other Investments - - 21,735
Short-term investments 30,138 61,825 45,551
Cash and bank balances 65,738 17,865 13,190
Total Liquid Funds 95,876 79,690 58,741
Total Current Assets 103,395 86,242 86,441
TOTAL ASSETS 140,751 105,642 104,119
SHAREHOLDERS' EQUITY AND LIABILITIES Note 4
Shareholders' Equity
Issued capital 9,772 8,735 8,735
Other Capital Contributions 349,995 420 288,938
Other Reserves 99 158,321 160
Accumulated Losses -227,691 -47,411 -203,201
Total Shareholders' Equity 132,175 120,065 94,632
Non-current liabilities - - -
Current Liabilities
Trade Payables 2,989 4,291 1,624
Other Payables 1,400 1,175 2,114
Prepaid Income and Accrued Expenses 4,187 3,780 5,749
Total Current Liabilities 8,576 9,246 9,487
TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES 140,751 129,311 104,119
Change in Shareholders' Equity
(kSEK)
Share Capital Other Capital Contributions Other reserves Accumulated
losses TOTAL
Adjusted opening balance, August 31, 2005 8,418 271,571 560 -164,551 115,998
Translation Gain 207 207
Revaluation of Short-Term Investments -607 -607
Option Premiums 240 240
New Share Issue 317 17,127 17,444
Net Loss for the Year -38,650 -38,650
Closing balance, August 31, 2006 8,735 288,938 160 -203,201 94,632
Opening balance, September 1, 2006 8,735 288,938 160 -203,201 94,632
New Share Issue 942 49,802 50,744
New Share Issue 70 10,030 10,100
Option Premiums 25 1,225 1,250
Translation Gain -61 -61
Net Loss for the Period -24,490 -24,490
Closing balance, February 28, 2007 9,772 349,995 99 -227,691 132,175
Cash Flow Statement
kSEK 6 months 6 months 3 months 3 months 12 months
Sep-Feb Sep-Feb Dec-Feb Dec-Feb Sep-Aug
2006-2007 2005-2006 2006-2007 2005-2006 2005-2006
Cash Flow from Operations before Changes in Working Capital
Operating loss -25,225 -15,005 -15,090 -6,487 -40,652
Interest Received 1,439 1,112 519 436 4,304
Interest Paid -528 - 548 - -56
Dividend Received - - - - -
Non-Cash Flow Items
Depreciation 1,160 - 550 - 1,740
Changes in Accrued Interest -176 381 -102 191 -2,496
Other Non-Cash Flow Items - 259 -1,055 203 1,933
Income Tax Paid -78 -56 -49 -56 -158
Net Cash Flow from Operating Activities before Changes in Working
Capital -23,408 -13,309 -14,679 -5,713 -35,385
Increase (-) Decrease (+) Inventory -2 -113 -5 -12 -5
Increase (-) Decrease (+) Receivables -1,478 1,162 4,082 -2,408 2,040
Increase (+) Decrease (-) Liabilities -854 -759 -3,336 252 680
Net Cash Flow from Operating Activities -25,742 -13,019 -13,938 -7,881 -32,670
Cash Flow from Investing Activities
Purchase of Intangible Assets -51 -50 -51 -22 -436
Purchase of Tangible Assets -185 - -68 - -28
Purchase of Financial Asserts 16,542 - 1,428 - -69,297
Net Cash Flow from Investing Activities 16,306 -50 1,309 -22 -69,761
Cash Flow from Financing Activities
Change in Long-Term Liabilities - - - - -768
Option premiums 1,225 - 1,225 - -
New share issue 60,869 818 10,125 818 1,058
- -23,669 - -23,669 -
Net Cash Flow from Financing Activities 62,094 -22,851 11,350 -22,851 290
Total Cash Flow for the Period 52,657 -35,920 -1,280 -30,754 -102,141
Cash and Cash Equivalents at beginning of
period 13,190 115,535 66,942 110,372 115,535
Net Foreign Exchange difference -109 25 76 22 -204
Cash and Cash Equivalents at end of period 65,738 79,640 65,738 79,640 13,190
Accounting Principles
The consolidated financial statements have been prepared in compliance with the
International Financial Reporting Standards (IFRS) established by the
International Accounting Standards Board (IASB) and the interpretations
published by the International Financial Reporting Interpretations Committee
(IFRIC) as endorsed by the European Commission for application in the EU. This
consolidated interim report has been prepared in accordance with IAS 34, Interim
Financial Reporting, which is consistent with the requirements stated in the
Swedish Financial Accounting Standards Council's recommendation RR 31, Interim
Reporting for Groups. The Group applies the same accounting and valuation
principles as in the annual report for 2005/2006.
Notes
Note 1. Sales
kSEK 6 months 6 months 3 months 3 months 12 months
Sep-Feb Sep-Feb Dec-Feb Dec-Feb Sep-Aug
2006-2007 2005-2006 2006-2007 2005-2006 2005-2006
Sales of GAD-protein and diagnostic products 170 474 112 260 707
Invoiced freight 6 14 4 10 14
Out-licensing of GAD-technology - - - - 3,602
Other operating income 381 107 360 107 -
TOTAL 557 595 476 377 4,323
Note 2 - Balance for the period
The business is making a loss. Deduction for losses in the Swedish company is
valued at SEK 0 as a precaution.
Note 3 - Financial Assets
The Company converted the US$ 3 million investment in Protein Sciences into an
equity position totaling approximately 6.7% on a fully-diluted basis.
Note 4 - Shareholders' equity and liabilities
All Company debts are non-interest-bearing.
Key ratios
6 months 6 months 3 months 3 months 12 months
Sep-Feb Sep-Feb Dec-Feb Dec-Feb Sep-Aug
2006-2007 2005-2006 2006-2007 2005-2006 2005-2006
Return on Equity, % -21.6 -11.8 -10.4 -5.3 -36.8
Return on Capital Employed, % -21.6 -11.8 -10.4 -5.3 -36.7
Return on Assets, % -20.0 -10.9 -9.8 -4.9 -33.6
Shareholders' Equity per Share, SEK 13.5 13.7 13.5 13.7 10.8
Shareholders' Equity per Share after dilution, SEK 13.7 14.1 13.5 13.9 11.0
Cash flow per share, SEK 5.5 -4.3 -0.1 -3.6 -11.9
Solidity, % 93.9 92.8 93.9 92.8 90.9
Earnings per share SEK -2.6 -1.6 -1.4 -0.7 -4.5
Earnings per share after dilution, SEK -2.6 -1.6 -1.4 -0.7 -4.5
Number of shares 9,772,478 8,735,216 9,772,478 8,735,216 8,735,216
Number of shares, Average 9,546,639 8,428,615 9,700,478 8,439,188 8,582,797
Number of shares, Diluted 9,642,786 8,531,266 9,799,739 8,635,284 9,544,076
Stockholm, April 20, 2007
The Board of Diamyd Medical AB (publ)
This report has not been reviewed by Diamyd Medical's auditors.
Financial Calendar
9-month report (March-May) June 29, 2007
Year End Report (September-August) October 26, 2007
For further information, please contact:
Stockholm-office
Anders Essen-Möller
CEO and President
Tel: +46 8 661 0026
E-mail: investor.relations@diamyd.com
Pittsburgh office
Michael Christini
President
Tel: +1 412 770 1310
E-mail: Michael.Christini@diamyd.com
For media contact in the US, please contact:
Gregory Tiberend
Executive Vice President
Richard Lewis Communications, Inc.
Tel: +1 212 827 0020
E-mail: gtiberend@rlcinc.com
Diamyd Medical AB (publ). Linnégatan 89 B, SE-115 23 Stockholm, Sweden. Tel: +46
8 661 00 26, fax: +46 8 661 63 68 or E-mail: info@diamyd.com. VATno:
SE556530-142001.
About Diamyd Medical
Diamyd Medical is a Life Science company focused on developing treatments for
diabetes and its complications. The Company's furthest developed project is the
GAD-based candidate drug Diamyd® for autoimmune diabetes. Diamyd® has
demonstrated significant and positive results in Phase II clinical trials in
both type 1 and autoimmune type 2 diabetes patients (LADA) in Sweden.
GAD65, a major autoantigen in autoimmune diabetes, is the active substance in
Diamyd®. GAD65 is also an enzyme that converts the excitatory neurotransmitter
glutamate to the inhibitory transmitter GABA. In this context GAD may have an
important role not only in diabetes, but also in several CNS-related diseases.
Diamyd Medical has an exclusive world-wide license from UCLA in Los Angeles
regarding the therapeutic use of the GAD65 gene.
Diamyd Medical has sublicensed its UCLA GAD65 Composition of Matter license to
Neurologix Inc., New Jersey, for treatment of Parkinson's disease with an
AAV-vector.
Other projects comprise drug development within gene therapy using the
exclusively licensed and patent protected Nerve Targeted Drug Delivery System
(NTDDS). The Company's lead gene therapy projects include using enkephalin and
GAD for chronic pain, e.g. diabetes pain or cancer pain. All projects in this
field are currently in preclinical phases.
Diamyd Medical has offices in Stockholm (Sweden) and in Pittsburgh (USA). The
Diamyd Medical share is quoted on the Stockholm Nordic Exchange in Sweden
(ticker symbol: DIAM B) and on the OTCQX-list in the US (ticker symbol: DMYDY)
administered by the Pink Sheets and the Bank of New York (PAL). Further
information is available at www.diamyd.com
Disclaimer: This document contains certain "statements" relating to present
understandings, future events and future performance, including statements
relating to the progress, timing and completion of our research, development and
clinical trials; our ability to market, commercialize and achieve market
acceptance for product candidates; and our current and future strategic partner
relationships. These statements can be affected by inaccurate assumptions or by
known or unknown risks and uncertainties. Diamyd Medical undertakes no
obligation to publicly update such statements, whether because of new
information, future events or otherwise, nor does Diamyd Medical give any
guarantees that the statements, given or implied, are correct. This document is
a translation from the Swedish original. No guarantees are made that the
translation is free from errors.
